96. THE PSA-RELATED KALLIKREIN ENZYMES AND HORMONE-DEPENDENT CANCERS

<u>Judith Clements</u>, Tara Veveris-Lowe, Loan Bui, Rachael Collard, Mitchell Lawrence, Dimitri Odorico, Frank Gardiner, David Nicol, Adrian Herington and Ying Dong

Hormone Dependent Cancer Program, School of Life Sciences & Cluster for Molecular Biotechnology, Science Research Centre, Queensland University of Technology and University of Queensland Department of Surgery, Royal Brisbane and Princess Alexandra Hospitals, Brisbane, QLD.

The human tissue kallikreins are a multigene family of 15 serine proteases, which are expressed in hormone-dependent cancers. Prostate-specific antigen or PSA, a member of this family, is the current serum biomarker for detection and monitoring of prostate cancer. Other kallikreins are being investigated as potential diagnostic/prognostic markers, particularly for prostate (KLK2) and ovarian cancer (KLKs 4-11 & 14, 15), the latter specifically as biomarkers for serous epithelial ovarian carcinomas. Interestingly, some ovarian KLKs (8, 9, 14 & 15) appeared to be useful indicators of good prognosis whereas others (KLKs 4, 5, 6, 7, 10 & 11) indicated a poor outcome. One novel aspect of the human KLKs is the number of differentially-spliced transcripts that could encode truncated proteins devoid of protease activity. We have shown that some variant transcripts (for PSA, KLK2, KLK4, KLK5 & KLK7) are more highly expressed than full-length transcripts in malignant compared to benign tissues suggesting they may have potential as more cancer-specific biomarkers. Intriguingly, some KLK4 variants are localized to the nucleus, which is not a typical intracellular site for a protease that is normally secreted, emphasizing possible non-proteolytic functions of these variants. From biochemical studies, it appears that kallikreins are involved in a range of functional activities via the degradation of polypeptides (extracellular matrix proteins, IGFBPs) or polypeptide activation via hydrolysis of the pro-peptide (uPA, TGFB). Although not yet proven, these observations suggest that kallikreins play a role in events associated with tumour progression. We have recently developed prostate cancer PC3 cell lines stably-transfected with prepro-PSA, -KLK2 and -KLK4. We have shown that PSA and KLK4 over-expression, but not KLK2, elicits a morphological change, increased migration to various chemo-attractants and increased attachment to extracellular matrix components (KLK4 only). The mechanisms underlying these changes are currently under investigation.